Last update 01 Nov 2024

REGN-10597

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Target
IL2RA x PD-1
Mechanism
IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases
Active Indication
Advanced Malignant Solid NeoplasmMelanomaRenal Cell Carcinoma+ [1]
Inactive Indication-
Originator Organization
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Active Organization
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with REGN-10597
NCT06413680 / Not yet recruitingPhase 1/2
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) in Patients With Advanced Solid Organ Malignancies
100 Clinical Results associated with REGN-10597
Login to view more data
100 Translational Medicine associated with REGN-10597
Login to view more data
100 Patents (Medical) associated with REGN-10597
Login to view more data
100 Deals associated with REGN-10597
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2-
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
05 Sep 2024
MelanomaPhase 2-
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
05 Sep 2024
Renal Cell CarcinomaPhase 2-
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
05 Sep 2024
NeoplasmsPreclinical
US
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
18 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free